About Lactobacillus brevis
Renamed from Lactobacillus brevis to Levilactobacillus brevis (2020). Some strain-specific work exists (CD2 for oral mucositis, KB290 for immune markers) but the clinical evidence is preliminary. Graded low; typically a blend/presence-only component.
What Lactobacillus brevis supports
- Preliminary evidence for immune and oral health (specific strains)
How much Lactobacillus brevis to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1–10
billion_cfu
No established therapeutic dose; strain trials (CD2, KB290) use ~1-10 billion CFU/day. Usually presence-only in blends; nominal range.
Clinical evidence
Limited clinical evidence. Low: preliminary, strain-specific data only.
Examine.com